Statera Biopharma, Inc. Overview
Pro stress-test →Statera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. In 2021, Cleveland BioLabs merged with Cytocom, Inc., and the new company renamed itself Statera BioPharma.
Strategic Profile
Pro stress-test →Through its Advanced Immunomodulating Multi-Component System (AIMS) platform, the company has advanced several late-stage developmental product candidates. The company has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.
Competitive Landscape
Pro stress-test →Statera competes in the immunotherapy and immune-modulation space against larger pharma players developing checkpoint inhibitors and novel immune modulators. Direct competitors include companies like Moderna (RNA immunotherapeutics), Adaptimmune (cellular immunotherapy), and academic/biotech programs at major cancer centers. The company's niche focus on immune homeostasis and TLR-based approaches differentiates it in a crowded space.
Industry Context
Statera Biopharma, Inc. operates in Clinical-stage immunotherapy and immune-modulation.
Key facts
Founded: 2003 · Headquarters: Fort Collins, US · Employees: ~50-100 · Revenue: N/A · Market cap: N/A